PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
NTLA vs. BEAM
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Performance

NTLA vs. BEAM - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Intellia Therapeutics, Inc. (NTLA) and Beam Therapeutics Inc. (BEAM). The values are adjusted to include any dividend payments, if applicable.

0.00%20.00%40.00%60.00%80.00%100.00%JuneJulyAugustSeptemberOctoberNovember
-0.88%
28.27%
NTLA
BEAM

Returns By Period

In the year-to-date period, NTLA achieves a -54.03% return, which is significantly lower than BEAM's -11.65% return.


NTLA

YTD

-54.03%

1M

-33.52%

6M

-45.87%

1Y

-50.16%

5Y (annualized)

-1.31%

10Y (annualized)

N/A

BEAM

YTD

-11.65%

1M

1.69%

6M

-2.32%

1Y

-12.45%

5Y (annualized)

N/A

10Y (annualized)

N/A

Fundamentals


NTLABEAM
Market Cap$1.70B$2.31B
EPS-$5.45-$1.58
Total Revenue (TTM)$43.09M$349.64M
Gross Profit (TTM)$35.51M$327.80M
EBITDA (TTM)-$521.07M-$166.30M

Key characteristics


NTLABEAM
Sharpe Ratio-0.74-0.06
Sortino Ratio-0.930.50
Omega Ratio0.891.05
Calmar Ratio-0.50-0.05
Martin Ratio-1.62-0.12
Ulcer Index28.40%36.82%
Daily Std Dev61.58%74.47%
Max Drawdown-92.10%-86.76%
Current Drawdown-92.07%-82.00%

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Correlation

-0.50.00.51.00.7

The correlation between NTLA and BEAM is 0.71, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.

Risk-Adjusted Performance

NTLA vs. BEAM - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Intellia Therapeutics, Inc. (NTLA) and Beam Therapeutics Inc. (BEAM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for NTLA, currently valued at -0.74, compared to the broader market-4.00-2.000.002.004.00-0.74-0.04
The chart of Sortino ratio for NTLA, currently valued at -0.93, compared to the broader market-4.00-2.000.002.004.00-0.930.53
The chart of Omega ratio for NTLA, currently valued at 0.89, compared to the broader market0.501.001.502.000.891.06
The chart of Calmar ratio for NTLA, currently valued at -0.50, compared to the broader market0.002.004.006.00-0.50-0.04
The chart of Martin ratio for NTLA, currently valued at -1.62, compared to the broader market0.0010.0020.0030.00-1.62-0.08
NTLA
BEAM

The current NTLA Sharpe Ratio is -0.74, which is lower than the BEAM Sharpe Ratio of -0.06. The chart below compares the historical Sharpe Ratios of NTLA and BEAM, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Rolling 12-month Sharpe Ratio-0.80-0.60-0.40-0.200.000.200.40JuneJulyAugustSeptemberOctoberNovember
-0.74
-0.04
NTLA
BEAM

Dividends

NTLA vs. BEAM - Dividend Comparison

Neither NTLA nor BEAM has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

NTLA vs. BEAM - Drawdown Comparison

The maximum NTLA drawdown since its inception was -92.10%, which is greater than BEAM's maximum drawdown of -86.76%. Use the drawdown chart below to compare losses from any high point for NTLA and BEAM. For additional features, visit the drawdowns tool.


-90.00%-85.00%-80.00%-75.00%JuneJulyAugustSeptemberOctoberNovember
-92.07%
-82.00%
NTLA
BEAM

Volatility

NTLA vs. BEAM - Volatility Comparison

Intellia Therapeutics, Inc. (NTLA) has a higher volatility of 29.12% compared to Beam Therapeutics Inc. (BEAM) at 24.02%. This indicates that NTLA's price experiences larger fluctuations and is considered to be riskier than BEAM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%15.00%20.00%25.00%30.00%JuneJulyAugustSeptemberOctoberNovember
29.12%
24.02%
NTLA
BEAM

Financials

NTLA vs. BEAM - Financials Comparison

This section allows you to compare key financial metrics between Intellia Therapeutics, Inc. and Beam Therapeutics Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items